Katie Kalvaitis

Dawn Marie R. Davis, MD, is professor of dermatology and pediatrics at Mayo Clinic in Rochester, Minnesota.

Lawrence F. Eichenfield, MD, is professor of dermatology and pediatrics and vice chair of the department of dermatology at the University of California, San Diego.

Tina Bhutani, MD, MAS, is associate clinical professor of dermatology at the University of California, San Francisco, and CEO of Synergy Dermatology.

NEW ORLEANS — Continuous glucose monitoring may have a role for adults with type 2 diabetes who are not using insulin, according to results from the CONNECT trial.“We know that CGM has been shown to be effective for individuals with any type of diabetes using insulin, but the data for the effectiveness of CGM for individuals with type 2 diabetes not on insulin is not as robust,”

NEW ORLEANS — Once-weekly survodutide was linked with substantial reductions in body weight and liver fat content among individuals with obesity and metabolic dysfunction-associated steatotic liver disease.

NEW ORLEANS — Weekly petrelintide demonstrated clinically meaningful weight loss through 42 weeks and was well tolerated among adults with obesity or overweight without diabetes, according to results from the phase 2 ZUPREME-1 trial.Petrelintide (Roche/Zealand Pharma) is a long-acting human amylin analog that is being investigated as a once-weekly injectable medication for obesity.

CHICAGO — At 2 years, crinecerfont demonstrated favorable effects on weight, body composition and insulin resistance in adults with congenital adrenal hyperplasia, researchers reported at ENDO 2026.

CHICAGO — In patients with acquired hypothalamic obesity, treatment with setmelanotide for 2.5 years was associated with sustained reductions in age-related weight metrics, according to findings from a long-term extension study. The study, presented at ENDO 2026, included 14 participants (12 younger than 18 years) who completed a 16-week phase 2 trial of setmelanotide (Imcivree, Rhythm

NEW ORLEANS —Adults with type 2 diabetes receiving once-daily orforglipron alongside insulin glargine had greater improvements in HbA1c than those receiving placebo, according to data from the ACHIEVE-5 trial.

NEW ORLEANS — Once-daily orforglipron induced greater reductions in HbA1c than dapagliflozin and oral semaglutide for adults with type 2 diabetes, according to findings from the ACHIEVE-2 and ACHIEVE-3 trials.